Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis.
PD-1 inhibitors
PD-L1 inhibitors
acute kidney injury
chronic kidney disease
immune-checkpoint inhibitors
meta-analysis
renal toxicity
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
27 Jul 2022
27 Jul 2022
Historique:
received:
03
06
2022
revised:
01
07
2022
accepted:
24
07
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
Aim: We performed a meta-analysis of the available clinical trials of immune-checkpoint inhibitors to assess risk differences and relative risks of renal toxicity. Methods: 17 randomized phase III studies were selected, including 10,252 patients. Results: The administration of immune-checkpoint inhibitors resulted in an overall low-grade, high-grade and all-grade renal toxicity Risk Difference of: 0.746% (95% CI 0.629% to 1.15%, p < 0.001—random), 0.61% (95% CI, 0.292−0.929%, p < 0.001—fixed) and 1.2% (95% CI, 0.601−1.85%—random), respectively. The pooled Relative Risk of low-grade, high-grade and all-grade renal toxicity was: 2.185 (95% CI 1.515−3.152—fixed), 2.610 (95% CI, 1.409−4.833, p = 0.002—fixed) and 2.473 (95% CI, 1.782−3.431, p < 0.001—fixed), respectively. An increased risk of renal toxicity was evident in some subgroups more than others. Conclusion: Immune-checkpoint inhibitors are associated with an increased risk of renal toxicity.
Identifiants
pubmed: 35955989
pii: jcm11154373
doi: 10.3390/jcm11154373
pmc: PMC9368813
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Am J Kidney Dis. 2016 Aug;68(2):287-291
pubmed: 27113507
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Clin Oncol (R Coll Radiol). 2017 Apr;29(4):218-230
pubmed: 27894673
J Immunol Res. 2018 Jun 3;2018:1027323
pubmed: 29971244
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
J Clin Oncol. 2017 Oct 20;35(30):3449-3457
pubmed: 28854067
Case Reports Immunol. 2018 Jun 13;2018:1623957
pubmed: 30009063
J Immunother Cancer. 2017 Nov 21;5(1):95
pubmed: 29162153
Lancet Oncol. 2014 Jun;15(7):700-12
pubmed: 24831977
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
J Immunother Cancer. 2019 Jan 6;7(1):2
pubmed: 30612580
Tumori. 2017 Sep 18;103(5):405-421
pubmed: 28497847
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Curr Med Chem. 2018;25(11):1327-1339
pubmed: 28403786
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Nephrol Dial Transplant. 2016 Apr;31(4):515-9
pubmed: 26341467
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Ther Adv Respir Dis. 2016 Jun;10(3):183-93
pubmed: 26944362
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Immunother Cancer. 2016 Oct 18;4:64
pubmed: 27777773
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
Int Immunopharmacol. 2018 Oct;63:292-298
pubmed: 30130720
Clin Genitourin Cancer. 2019 Oct;17(5):e903-e908
pubmed: 31375351
Ann Oncol. 2020 Jan;31(1):50-60
pubmed: 31912796
J Am Soc Nephrol. 2020 Feb;31(2):435-446
pubmed: 31896554
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Kidney Int. 2016 Sep;90(3):638-47
pubmed: 27282937
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Invest New Drugs. 2019 Jun;37(3):579-583
pubmed: 30298302
Int J Cancer. 2017 Sep 1;141(5):1018-1028
pubmed: 28263392
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Eur J Cancer. 2021 Nov;157:50-58
pubmed: 34482189
Immunotherapy. 2016 May;8(5):665-74
pubmed: 27140415
Int J Surg. 2010;8(5):336-41
pubmed: 20171303